Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van Guselkumab versus Placebo voor de behandeling van matige plaque-psoriasis met een laag lichaamsoppervlak (SPECTREM)

10 april 2026 bijgewerkt door: Janssen Research & Development, LLC

Een fase 3b, multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde studie ter evaluatie van de veiligheid en werkzaamheid van guselkumab versus placebo voor de behandeling van matige plaquepsoriasis met een lage lichaamsoppervlakte (BSA) waarbij speciale locaties betrokken zijn

Het doel van deze studie is om de werkzaamheid van guselkumab te evalueren in vergelijking met een inactief geneesmiddel bij deelnemers met een laag lichaamsoppervlak, matige plaque psoriasis en betrokkenheid van speciale plaatsen.

Studie Overzicht

Toestand

Voltooid

Studietype

Ingrijpend

Inschrijving (Werkelijk)

338

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alberta
      • Calgary, Alberta, Canada, T3E 0B2
        • Beacon Dermatology
      • Edmonton, Alberta, Canada, T5J 3S9
        • Rejuvenation Dermatology Clinic Edmonton Downtown
    • British Columbia
      • Surrey, British Columbia, Canada, V3V 0C6
        • Enverus Medical
      • Surrey, British Columbia, Canada, V3R 6A7
        • Dr. Chih ho Hong Medical
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3M 3Z4
        • Wiseman Dermatology Research Inc.
      • Winnipeg, Manitoba, Canada, R3C 0N2
        • Winnipeg Clinic
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 1G9
        • Brunswick Dermatology Center
    • Ontario
      • Ajax, Ontario, Canada, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Canada, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Canada, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, Canada, N6H 5L5
        • Dr Wei Jing Loo Medicine Professional Corporation
      • North York, Ontario, Canada, M2M 4J5
        • North York Research Inc
      • Ottawa, Ontario, Canada, K1H 7X3
        • JRB Research Inc
      • Toronto, Ontario, Canada, M4W 2N2
        • Research Toronto
      • Toronto, Ontario, Canada, M3H 5Y8
        • Toronto Research Centre
      • Toronto, Ontario, Canada, M3B 0A7
        • Canadian Dermatology Center
      • Toronto, Ontario, Canada, M4E 2Y9
        • FACET Dermatology
      • Waterloo, Ontario, Canada, N2J 1C4
        • K. Papp Clinical Research Inc.
    • Quebec
      • Québec, Quebec, Canada, G1W 4R4
        • The Centre de recherche Saint-Louis
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35244
        • Cahaba Research Inc
      • Birmingham, Alabama, Verenigde Staten, 35203
        • Total Dermatology
    • California
      • Encinitas, California, Verenigde Staten, 92024
        • California Dermatology & Clinical Research Institute
      • Fountain Valley, California, Verenigde Staten, 92708
        • First OC Dermatology
      • Riverside, California, Verenigde Staten, 92505
        • Practice Wang
      • San Diego, California, Verenigde Staten, 92123
        • Therapeutics Clinical Research
      • Santa Ana, California, Verenigde Staten, 92701
        • Rehlen, Bartlow, Goodman and Baron Dermatology Group
      • Santa Monica, California, Verenigde Staten, 90404
        • Clinical Science Institute
    • Connecticut
      • Farmington, Connecticut, Verenigde Staten, 06030
        • University of Conn Health Center
    • Florida
      • Brandon, Florida, Verenigde Staten, 33511
        • TrueBlue Clinical Research
      • Coral Gables, Florida, Verenigde Staten, 33134
        • Florida Academic Dermatology Centers
      • Doral, Florida, Verenigde Staten, 33122
        • Revival Research
      • Margate, Florida, Verenigde Staten, 33063
        • Glick Research Institute
      • Miami, Florida, Verenigde Staten, 33124
        • Miami VA Healthcare System
      • North Miami Beach, Florida, Verenigde Staten, 33162
        • Tory P Sullivan M D PA
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 303331
        • Atlanta Biomedical Clinical Research
    • Maryland
      • Columbia, Maryland, Verenigde Staten, 21045
        • Kindred Hair and Skin Center
      • Rockville, Maryland, Verenigde Staten, 20850
        • DermAssociates, PC
      • Rockville, Maryland, Verenigde Staten, 20850
        • Lawrence J Green MD LLC
    • Massachusetts
      • Brighton, Massachusetts, Verenigde Staten, 02135
        • Metro Boston Clinical Partners
      • Quincy, Massachusetts, Verenigde Staten, 02169
        • DermCare, LLC
    • Michigan
      • West Bloomfield, Michigan, Verenigde Staten, 48322
        • Henry Ford Medical Center
    • New York
      • New York, New York, Verenigde Staten, 10003
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Verenigde Staten, 10128
        • Markowitz Medical OptiSkin
    • North Carolina
      • Cary, North Carolina, Verenigde Staten, 27511
        • Accellacare Research of Cary
      • Charlotte, North Carolina, Verenigde Staten, 28277
        • Darst Dermatology
      • Huntersville, North Carolina, Verenigde Staten, 28078
        • Piedmont Plastic Surgery and Dermatology
    • Ohio
      • Bexley, Ohio, Verenigde Staten, 43209
        • Bexley Dermatology Research
      • Columbus, Ohio, Verenigde Staten, 43215
        • Remington Davis Inc
      • Mayfield Heights, Ohio, Verenigde Staten, 44124
        • Apex Dermatology Mayfield Heights
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29414
        • Dermatology and Laser Center of Charleston
      • Fountain Inn, South Carolina, Verenigde Staten, 29644
        • Palmetto Clinical Trial Services, LLC
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37215
        • Tennessee Clinical Research Center
      • Nashville, Tennessee, Verenigde Staten, 37212
        • Nashville Skin: Comprehensive Dermatology Center
    • Texas
      • Arlington, Texas, Verenigde Staten, 76011
        • Arlington Center for Dermatology
      • Bellaire, Texas, Verenigde Staten, 77401
        • Bellair Dermatology
      • Dallas, Texas, Verenigde Staten, 75231
        • Modern Research Associates PLLC
      • Dallas, Texas, Verenigde Staten, 75246
        • Menter Dermatology Research Institute
      • Dallas, Texas, Verenigde Staten, 75235
        • Bare Dermatology
      • Houston, Texas, Verenigde Staten, 77004
        • Center for Clinical Studies
      • Houston, Texas, Verenigde Staten, 77056-4132
        • Suzanne Bruce and Associates - The Center for Skin Research
      • San Antonio, Texas, Verenigde Staten, 78229
        • Progressive Clinical Research
      • San Antonio, Texas, Verenigde Staten, 78218
        • Texas Dermatology and Laser Specialists
      • Sugar Land, Texas, Verenigde Staten, 77479
        • Acclaim Dermatology
    • Washington
      • Mill Creek, Washington, Verenigde Staten, 98102
        • Frontier Derm Partners CRO, LLC

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusiecriteria:

  • Alle deelnemers moeten ten minste 6 maanden vóór de eerste toediening van de onderzoeksinterventie een diagnose van plaque psoriasis (met of zonder artritis psoriatica) hebben
  • Alle deelnemers moeten bij de screening en bij baseline aan de volgende criteria voor de ernst van de ziekte voldoen: (a) Overall Investigator's Global Assessment (IGA) 3 (matige) plaque psoriasis; (b) Lichaamsoppervlak (BSA) 2-15 procent (%) met minstens 1 plaque buiten speciale locaties; (c) Betrokkenheid van ten minste één speciale locatie met ten minste matige ernst. Kwalificerende locaties zijn onder meer de hoofdhuid met hoofdhuidspecifieke IGA groter dan of gelijk aan (>=) 3, gezicht met gezichtspsoriasis IGA >=3, intertrigineus met intertrigineuze psoriasis IGA >=3, of genitaal met algemene beoordeling door een statische arts van genitaliën (sPGA- G) >=3
  • Alle deelnemers zijn onvoldoende onder controle met of zijn intolerant voor ten minste één eerdere plaatselijke behandeling (waaronder, maar niet beperkt tot, corticosteroïden, retinoïden, vitamine D, of vitamine D/steroïde en retinoïde/steroïde combinaties, tacrolimus, pimecrolimus, antraline/dithranol, kool teerpreparaten, tapinarof, roflumilast, etcetera) voor de behandeling van psoriasis bij beide screeningen
  • Alle deelnemers komen in aanmerking voor fototherapie of systemische behandeling voor psoriasis

Uitsluitingscriteria:

  • Heeft een niet-plaque vorm van psoriasis (bijvoorbeeld erytrodermisch, guttaat of pustulair) bij screening of randomisatie
  • Heeft momenteel door geneesmiddelen geïnduceerde psoriasis (bijvoorbeeld een nieuw begin van psoriasis of een verergering van psoriasis door bètablokkers, calciumantagonisten of lithium)
  • Voor deelnemers met palmoplantaire betrokkenheid moeten verwarrende diagnoses, waaronder maar niet beperkt tot palmoplantaire pustulose, eczemateuze dermatitis, contact/irriterende dermatitis, verworven keratodermie, enzovoort, worden bevestigd en uitgesloten.
  • Deelnemers komen niet in aanmerking als ze ooit eerder biologische geneesmiddelen (of biosimilars daarvan) hebben ontvangen voor de behandeling van psoriasis, artritis psoriatica (PsA) of andere indicaties die van invloed kunnen zijn op de beoordeling van psoriasis. Eerdere biologische geneesmiddelen (of biosimilars daarvan) kunnen omvatten, maar zijn niet beperkt tot, tumornecrosefactor (TNF)-remmers (bijvoorbeeld: adalimumab, etanercept, infliximab of certolizumab of biosimilars), interleukine (IL)-17-remmers (bijvoorbeeld: secukinumab, ixekizumab, brodalumab of bimekizumab) en IL-12/23-remmers (bijvoorbeeld: ustekinumab) of IL-23-remmer (bijvoorbeeld: guselkumab, risankizumab of tildrakizumab)
  • Heeft een voorgeschiedenis van chronische of terugkerende infectieziekten, waaronder, maar niet beperkt tot, chronische nierinfectie, chronische infectie van de borstkas (bijvoorbeeld bronchiëctasie), terugkerende urineweginfectie (terugkerende pyelonefritis of chronische aanhoudende cystitis), schimmelinfectie (mucocutane infectie). candidiasis), of open, drainerende of geïnfecteerde huidwonden of zweren

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Groep 1: Guselkumab
Deelnemers krijgen guselkumab toegediend via een subcutane injectie met placebo, indien nodig om de blinden in stand te houden.
Placebo zal als subcutane injectie worden toegediend.
Guselkumab zal als subcutane injectie worden toegediend.
Andere namen:
  • Tremfya
  • CNTO1959
Placebo-vergelijker: Groep 2: Placebo
Deelnemers krijgen een placebo via subcutane injectie en vervolgens guselkumab via subcutane injectie.
Placebo zal als subcutane injectie worden toegediend.
Guselkumab zal als subcutane injectie worden toegediend.
Andere namen:
  • Tremfya
  • CNTO1959

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
Tijdsspanne: Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
Week 16

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percent Change From Baseline in Body Surface Area (BSA) at Week 16
Tijdsspanne: Baseline (Week 0), Week 16
Percent change from baseline in BSA at Week 16 was reported. A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1 percent (%) BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Total Score at Week 16
Tijdsspanne: Baseline (Week 0), Week 16
Percent change from baseline in PASI total score at Week 16 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16
Tijdsspanne: Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
Week 16
Percentage of Participants Who Achieved PASI 90 Response at Week 16
Tijdsspanne: Week 16
Percentage of participants who achieved PASI 90 score (greater than or equal to [>=] 90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved PASI 100 Response at Week 16
Tijdsspanne: Week 16
Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 Among Randomized Participants With Ss-IGA Score >=3 at Baseline
Tijdsspanne: Week 16
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 at Week 16 Among Randomized Participants With sPGA-G Score >=3 at Baseline
Tijdsspanne: Week 16
The sPGA-G was a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis was assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5). Higher score indicates more severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Intertriginous IGA (i-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With an i-IGA Score >=3 at Baseline
Tijdsspanne: Week 16
The IGA used for the full body assessment was adapted with descriptions of disease features that were more consistent with intertriginous psoriasis presentation. The intertriginous areas assessed included the axillary, sub mammary, abdominal fold, inguinal, and intergluteal cleft/peri-anal region (distinct from genital/perineum involvement). The i-IGA was 5-point scale evaluating the severity of plaque psoriasis in the intertriginous area with scores defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated greater disease severity. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Percentage of Participants Who Achieved Facial IGA (f-IGA) Score of Clear (0) or Minimal (1) at Week 16 Among Randomized Participants With f-IGA Score >=3 at Baseline
Tijdsspanne: Week 16
The standard IGA used for full body evaluation was adapted for assessment of psoriasis on the face only. The f-IGA used a 5-point scale to assess overall facial disease severity, defined as clear (0), minimal (1), mild (2), moderate (3), and severe (4). A higher score indicated more severe facial psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Change From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Total Symptom Score at Week 16
Tijdsspanne: Baseline (Week 0), Week 16
The PSSD was a patient reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (>=50 percentage of 5 items) on these scales were answered. The average value was converted into 0-100 scoring, such that symptom score = average value*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Baseline (Week 0), Week 16
Percentage of Participants Who Achieved >=4-Point Improvement From Baseline in PSSD Itch Score at Week 16 Among Participants With a PSSD Itch Score >=4 at Baseline
Tijdsspanne: Week 16
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms(itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. Baseline was defined as the closest measurement taken prior to or at time of first study drug administration date.
Week 16
Percentage of Participants Who Achieved PSSD Individual Symptom Scale Score=0 at Week 16 Among Participants With a PSSD Symptom Score >0 at Baseline
Tijdsspanne: Week 16
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. 7-day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.
Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
Tijdsspanne: Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56
An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
Group 1: Placebo: From Week 0 to Week 16; Group 1: Placebo followed by Guselkumab 100 mg: From Week 16 to Week 56; Group 2: Guselkumab 100 mg: From Week 0 to Week 56

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 augustus 2023

Primaire voltooiing (Werkelijk)

14 april 2025

Studie voltooiing (Werkelijk)

14 april 2025

Studieregistratiedata

Eerst ingediend

9 september 2023

Eerst ingediend dat voldeed aan de QC-criteria

9 september 2023

Eerst geplaatst (Werkelijk)

15 september 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

10 april 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • CR109328
  • CNTO1959PSO3017 (Andere identificatie: Janssen Research & Development, LLC)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Het beleid voor het delen van gegevens van de Janssen Pharmaceutical Companies van Johnson & Johnson is beschikbaar op www.janssen.com/clinical-trials/transparency. Zoals vermeld op deze site, kunnen verzoeken om toegang tot de onderzoeksgegevens worden ingediend via de Yale Open Data Access (YODA) Project-site op yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren